
Eli Lilly and Company, Revolution Medicines, and Novo Nordisk A/S are the three Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks are shares of publicly traded companies whose primary businesses are in the healthcare sector—such as pharmaceuticals, biotechnology, medical devices, diagnostics, hospitals and health insurers. Investors buy them to gain exposure to healthcare, but their performance is influenced by drug trials and approvals, regulatory and reimbursement policies, patent expirations, and broader demographic and economic trends. These companies had the highest dollar trading volume of any Medical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Revolution Medicines (RVMD)
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Read Our Latest Research Report on RVMD
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Read Our Latest Research Report on NVO
Recommended Stories
- MarketBeat’s Top Five Stocks to Own in January 2026
- 3 Stocks Where Insiders Are Buying, Not Bailing
- These 3 Underrated ETFs Could Boom in 2026
- NVIDIA’s Next Leg Higher May Have Started at CES
- MarketBeat Week in Review – 01/05 – 01/09
- Warner Bros. Rejects Paramount’s Offer—How It Affects WBD, NFLX, PSKY
